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Abstract The importance of the individual amino acid residues
of AIP (KKALRRQEAVDAL), a highly specific inhibitor of
calmodulin-dependent protein kinase II (CaMKII), was studied.
Replacement of Arg6, Gln7, or Ala9 by other amino acid residues
produced a marked increase in the IC50 value. Leu4 and Val10
were also sensitive to replacement, but some hydrophobic amino
acids could substitute for these residues. Although replacement of
Ala3, Glu8, Ala12, and Leu13 by other residues produced no
significant increase in the IC50, the substitution of Lys for Ala3
decreased the IC50. An AIP analog (KKKLRRQEAFDAY), in
which Ala3 and Val10 were replaced with Lys and Phe,
respectively, showed an IC50 value as low as 4 nM, suggesting
that it is a useful tool for studying the physiological roles of
CaMKII.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Calmodulin-dependent protein kinase II (CaMKII) is
known to be a second-messenger-responsive multifunctional
protein kinase, which plays important roles in controlling a
variety of cellular functions in response to an increase in intra-
cellular Ca2, especially in the central nervous system [1^4].
For studying the physiological roles of CaMKII, a selective
and potent inhibitor of the enzyme is a useful tool. We have
recently demonstrated that a synthetic peptide, designated as
AIP, a nonphosphorylatable analog of a peptide substrate,
autocamtide-2 [5], is a highly speci¢c and potent inhibitor of
CaMKII [6]. AIP is 50 and 500 times more potent than
CaMK-(281^302 Ala286) and KN-93, respectively, which
have been widely used as CaMKII-speci¢c inhibitors, under
the assay conditions used. The inhibition by AIP is not af-
fected by Ca2/calmodulin, unlike those by KN series inhib-
itors. The use of AIP has recently revealed the involvement of
CaMKII in cyclic ADP-ribose-mediated intracellular Ca2
mobilization in pancreatic islets [7], Ca2/calmodulin-depend-
ent phosphorylation of AMPA type glutamate receptor sub-
units in the post-synaptic density [8], and phosphorylation of
phosrestin I, a homolog of arrestin which is involved in light
inactivation of rhodopsin in Drosophila [9]. Similar peptides to
AIP have also been used to examine the role of CaMKII in
the induction and maintenance of long-term potentiation in
the CA1 region of the rat hippocampal slice [10]. Thus, the
development of a potent speci¢c inhibitor of CaMKII will
o¡er a strong means to explore its physiological function.
2. Materials and methods
2.1. Materials
ATP and 1,2-dioleoyl-rac-glycerol were purchased from Sigma.
Phosphatidylserine was from Serdary Research Laboratories, Inc. [Q-
32P]ATP (5000 Ci/mmol) was from Amersham International. Syntide-
2 [11], a synthetic peptide substrate, was synthesized by American
Peptide Company, Inc. AIP (KKALRRQEAVDAL) [6,12] and its
analogs were synthesized by a Shimadzu PSSM-8 automated peptide
synthesizer as described previously [13]. Fmoc-L amino acids used for
the peptide synthesis were obtained from BACHEM and Shimadzu.
All these peptides were puri¢ed by reversed-phase HPLC, and their
molecular masses were con¢rmed by mass spectrometry on a time-of-
£ight mass spectrometer (Shimadzu/Kratos Kompact MALDI II)
with matrix-assisted laser desorption ionization as described [13].
Concentrations of the peptides containing Tyr were determined spec-
trophotometrically using an absorption coe⁄cient (O278) of 1.16U103
M31 cm31 [13]. Concentrations of the peptides without Tyr were
determined by amino acid analysis.
2.2. Protein preparations
CaMKII was puri¢ed from rat cerebral cortex as described previ-
ously [14]. Catalytic subunit of cyclic AMP-dependent protein kinase
(PKA) was prepared from bovine heart as described [15]. Protein
kinase C (PKC) was puri¢ed from rat cerebral cortex essentially ac-
cording to the method of Woodgett and Hunter [16]. Calmodulin-
dependent protein kinase IV (CaMKIV) was prepared as described
previously [17]. Calmodulin was puri¢ed from Escherichia coli trans-
formed with expression vector pET11d carrying a cDNA encoding
chicken brain calmodulin [6,14]. ‘CaM kinase II-depleted’ prepara-
tions of a rat brain extract, ‘P-through’ preparation, the £ow-through
fraction of a phosphocellulose column, and ‘CaM-through’ prepara-
tion, the £ow-through fraction of a calmodulin-Sepharose column,
were obtained as described previously [6].
2.3. Assay of protein kinases
The activities of CaMKII (0.31 Wg/ml), CaMKIV (3.46 Wg/ml),
PKA (0.80 Wg/ml) and PKC (0.33 Wg/ml) were measured as described
previously [6]. The activities in the presence of various concentrations
of inhibitors were expressed as percentages of those determined in
their absence. The IC50 was de¢ned as the concentration of the inhib-
itor which gave 50% inhibition.
2.4. Other analytical procedures
The concentrations of CaMKII and calmodulin were determined
spectrophotometrically as described previously [14]. The concentra-
tion of CaMKIV was determined as described [17]. Other proteins
were determined by the method of Lowry et al. [18], as modi¢ed by
Peterson [19], with bovine serum albumin as a standard. SDS-poly-
acrylamide gel electrophoresis was carried out according to the meth-
od of Laemmli [20].
FEBS 20172 1-5-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 4 0 5 - 0
*Corresponding author. Fax: +81 (166) 65-9416.
E-mail: fujisawa@asahikawa-med.ac.jp
Abbreviations: CaMKII, calmodulin-dependent protein kinase II;
CaMKIV, calmodulin-dependent protein kinase IV; PKA, cyclic
AMP-dependent protein kinase; PKC, protein kinase C
FEBS 20172 FEBS Letters 427 (1998) 115^118
3. Results and discussion
To know which amino acids of AIP are important for in-
hibition of CaMKII, the inhibitory activities of AIP analogs
in which each amino acid of AIP was replaced by Ala (Ala
scanning) or Tyr (Tyr scanning) residue were examined as
shown in Table 1. The IC50 values were determined from
the inhibition curves of the respective AIP analogs. Some
typical inhibition curves of AIP and AIP analogs are given
in Fig. 1. The substitution of Ala or Tyr for the residues Ala3,
Glu8, Ala12 or Leu13 (the amino acids are numbered starting
at the amino terminus) did not signi¢cantly increase the IC50
value of the peptide, suggesting that the side chains of amino
acid residues 3, 8, 12 and 13 were not essential for its inhib-
itory action. On the other hand, the replacement of Lys1,
Lys2, Arg5, or Asp11 by Ala or Tyr increased the IC50 by 4-
to 12-fold, and the replacement of Leu4, Arg6, Gln7, Ala9, or
Val10 increased the IC50 by more than 20-fold (except for
V10Y), suggesting the importance of these amino acid resi-
dues.
For obtaining further information about contribution of
each amino acid of AIP to the inhibitory action, the IC50
values of a number of substituted AIP analogs were deter-
mined as shown in Table 2. For easy determination of the
concentration of the AIP analogs, the C-terminal Leu13 of
AIP was replaced with Tyr in the analogs, since the substitu-
tion of Tyr for Leu13 did not signi¢cantly a¡ect the inhibitory
action of AIP (Fig. 1). We examined whether or not Leu4
could be replaced with another hydrophobic amino acid res-
idue, but none of several residues tested could decrease the
IC50 value. Replacement of Arg6 with another positively
charged hydrophilic amino acid produced an increase in the
IC50, but the extent of the increase was an order of magnitude
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Table 1
Ala scanning and Tyr scanning analysis of AIP
Position Residue Substitution Analogs IC50 (nM) IC50 (analog)/IC50 (AIP)
AIP 32
1 Lys Ala K1A 238 7.4
Tyr K1Y 391 12
2 Lys Ala K2A 162 5.1
Tyr K2Y 198 6.2
3 Ala Tyr A3Y 41 1.3
4 Leu Ala L4A V12 000 V375
Tyr L4Y 718 22
5 Arg Ala R5A 397 12
Tyr R5Y 281 8.8
6 Arg Ala R6A V30 000 V940
Tyr R6Y V21 000 V660
7 Gln Ala Q7A 1500 47
Tyr Q7Y 3700 116
8 Glu Ala E8A 21 0.66
Tyr E8Y 24 0.75
9 Ala Tyr A9Y 727 23
10 Val Ala V10A 1800 56
Tyr V10Y 271 8.5
11 Asp Ala D11A 371 12
Tyr D11Y 116 3.6
12 Ala Tyr A12Y 22 0.69
13 Leu Ala L13A 23 0.72
Tyr L13Y 26 0.81
Fig. 1. Inhibition of CaMKII by AIP analogs. CaMKII activities
were determined in the presence of the indicated concentrations
of AIP (b), K1A-AIP (a) and L13Y-AIP (O), as described in Sec-
tion 2.
Fig. 2. Inhibition of several protein kinases by A3K/V10F-AIP. The
activities of CaMKII (b), CaMKIV (a), PKA (R) and PKC (O)
were measured in the presence of the indicated concentrations of
A3K/V10F-AIP as described in Section 2.
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lower than that produced by the substitution of Ala or Tyr,
suggesting the importance of a positively charged amino acid
in this position of AIP. Although replacement of Arg5 with
Lys or His increased the IC50, the e¡ects of the replacements
were signi¢cantly smaller than those at the position 6. Re-
placement of Gln7 with another amino acid, even Asn, pro-
duced a relatively great increase in the IC50, suggesting the
importance of Gln in this position. Replacement of Ala9 with
other amino acids also produced a marked increase in the
IC50. Since substitutions at the position 8 have no e¡ect (Ta-
ble 1), it is interesting that the adjacent positions 7 and 9 are
highly susceptible to substitution. When substituted for Val10,
some amino acids increased the IC50, but Phe and Ile de-
creased the IC50 by 4-fold and 2-fold, respectively. Thus, the
position 10 appears to be more tolerant for substitution than
the position 4, though both of them absolutely require hydro-
phobic side chains.
Interestingly, the substitution of Lys for Ala3 also decreased
the IC50 by 3- to 4-fold, and thus the substitutions of Phe for
Val10 and Lys for Ala3 of AIP (A3K/V10F-AIP, Table 2)
produced an almost 10-fold decrease in the IC50. The appa-
rent IC50 value of the A3K/V10F analog for CaMKII was as
low as 4.1 nM, and this value is the lowest so far reported for
CaMKII inhibitors. Since the apparent IC50 value is compar-
able to the concentration of the enzyme used for the experi-
ment, the actual IC50 should be lower, because the IC50 value
largely depends on the concentration of the enzyme in such
cases [21]. The selectivity of the A3K/V10F analog was exam-
ined with four representative second-messenger-responsive
multifunctional protein kinases, PKA, PKC, CaMKIV, and
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Table 2
IC50 values of various substituted analogs of AIP
Position Residue Substitution Analogs* IC50 (nM) IC50 (analog)/IC50 (AIP)
AIP 32
3 Ala Lys A3K 9.2 0.29
4 Leu Phe L4F 57 1.8
Norleucine L4Nle 66 2.1
Ile L4I 171 5.3
Norvaline L4Nva 247 7.7
Met L4M 363 11
Val L4V 418 13
Gly L4G s 70 000 s 2200
5 Arg Lys R5K 66 2.1
His R5H 173 5.4
6 Arg Orn R6Orn 285 8.9
Lys R6K 338 11
NG ,NG -dimethyl-arginine R6dmR 960 30
Citrulline R6Cit 1200 38
His R6H 4300 134
7 Gln Glu Q7E 2600 81
Asp Q7D 5100 159
Asn Q7N 6800 213
Orn Q7Orn 8600 269
9 Ala Gly A9G 344 11
Cys A9C 354 11
Val A9V 938 29
Ile A9I 2800 88
Leu A9L 3700 116
10 Val Phe V10F 8.0 0.25
Ile V10I 16 0.50
Leu V10L 39 1.2
Norvaline V10Nva 60 1.9
2-Aminobutylic acid V10Abu 231 7.2
Gly V10G 5200 163
3, 10 Ala3/Val10 Lys3/Phe10 A3K/V10F 4.1 0.13
*The C-terminal residue of the AIP analogs shown in this table except R5H was replaced with Tyr.
Fig. 3. E¡ect of A3K/V10F-AIP on the endogenous phosphoryla-
tion of the rat brain extract which was depleted of CaM kinase II.
Two ‘CaM kinase II-depleted’ preparations of a rat brain extract,
‘P-through’ preparation (0.80 mg/ml, lanes 1^6) and ‘CaM-through’
preparation (0.26 mg/ml, lanes 7^12), were incubated at 30‡C for
1 min in the mixture consisting of 40 mM HEPES-NaOH (pH 8.0),
5 mM magnesium acetate, 0.1 mM EGTA, 1 WM calmodulin, 0.01%
Tween-20, and 50 WM [Q-32P]ATP, containing 1 mM CaCl2 (lanes 1,
2, 5^8, 11, 12), 0.1 WM A3K/V10F-AIP (lanes 1, 3, 5, 7, 9, 11) or
0.96 Wg/ml of puri¢ed CaM kinase II (lanes 5, 6, 11, 12). After in-
cubation, 22.7 mM EDTA was added to stop the kinase reaction,
and aliquots were subjected to SDS-polyacrylamide gel electrophore-
sis on a 10% polyacrylamide gel, followed by autoradiography.
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CaMKII, as shown in Fig. 2. Among them, the activities of
PKA and CaMKIV were not inhibited at all. The activity of
PKC was inhibited at a concentration of the A3K/V10F ana-
log as high as 10 WM, but not signi¢cantly inhibited at a
concentration (1 WM) more than two orders of magnitude
higher than the IC50 for CaMKII (4.1 nM). The selectivity
of the analog was also examined with two ‘CaM kinase II-
depleted’ preparations of a rat brain extract, ‘P-through’ and
‘CaM-through’ preparations, which were prepared by two dis-
tinct procedures as described in Section 2 (Fig. 3). The A3K/
V10F analog (0.1 WM) did not signi¢cantly a¡ect the endog-
enous phosphorylation of both preparations (lanes 1^4 and 7^
10), whereas phosphorylation of the two preparations caused
by the addition of puri¢ed CaM kinase II was markedly in-
hibited by 0.1 WM A3K/V10F-AIP (lanes 5, 6, 11, 12). These
results indicate that 0.1 WM of the analog had no e¡ect on the
activities of protein kinases other than CaM kinase II in the
brain extract, whereas it markedly inhibited the phosphoryla-
tion by CaM kinase II. Thus, the A3K/V10F-AIP is a very
potent and speci¢c inhibitor, and it will provide a strong
means for studying the physiological functions of CaMKII.
The question of whether the peptide inhibitor is susceptible
to proteolytic degradation in cells is important. It has been
reported that acetylation and amidation of N- and C-termi-
nals, respectively, of an AIP analog greatly enhances its e¡ec-
tiveness in neuronal cells, probably owing to the increased
resistivity to proteolysis [10]. Replacement of the Arg residue
within the Arg cluster of a peptide inhibitor of PKA, PKI(6^
24), with D-Arg is e¡ective in increasing the in vivo half-life of
the peptide [22]. Considering that Lys1 (N-terminus), Arg5,
and Leu13 (C-terminus) of AIP can be replaced by other ami-
no acid residues without leading to a great decrease in the
inhibitory e¡ect, such modi¢cations or substitutions may im-
prove resistivity to proteolytic degradation without signi¢cant
loss of their inhibitory potencies.
Based on speci¢city analysis using an oriented degenerate
peptide library, Songyang et al. [23] have recently reported
that a virtual optimal substrate sequence for CaMKII is
KRQQSFDLF, and that CaMKII prefers Arg at the 33 po-
sition, Gln at the 32 position and Phe at the +1 position in its
substrate (Fig. 4). Since AIP is a nonphosphorylatable analog
of autocamtide-2 (KKALRRQETVDAL), of which phos-
phorylation site is Thr9, AIP and the virtual optimal peptide
substrate can be aligned as shown in Fig. 4. Thus, the optimal
sequence of the peptide substrate suggested by them are in
good agreement with that of the inhibitory peptide obtained
in the present study. Since AIP inhibits CaMKII by binding
to the substrate-binding site for autophosphorylation site,
which is distinct from the binding site for the exogenous sub-
strate such as syntide-2 [6,12], the optimal sequence of CaM-
KII substrate reported by Songyang et al. appears to be not
for the exogenous substrate but for the autophosphorylation
site.
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Fig. 4. Alignment of amino acid sequences of AIP and a virtual optimal peptide substrate reported by Songyang et al. [23]. The amino acid
residues of AIP which are essential for the potent inhibition of CaMKII are indicated by bold letters. The substitutions which markedly reduce
the IC50 value are shown in italics below the residue numbers. In the sequence of the virtual optimal substrate, the residues which CaMKII
prefers strongly are shown in bold letters. The amino acid residue which is phosphorylated by CaMKII is numbered 0, in the virtual optimal
substrate.
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